1. Home
  2. DNA vs LXRX Comparison

DNA vs LXRX Comparison

Compare DNA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ginkgo Bioworks Holdings Inc.

DNA

Ginkgo Bioworks Holdings Inc.

HOLD

Current Price

$6.70

Market Cap

607.1M

Sector

Health Care

ML Signal

HOLD

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.47

Market Cap

547.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNA
LXRX
Founded
2008
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
607.1M
547.4M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
DNA
LXRX
Price
$6.70
$1.47
Analyst Decision
Hold
Buy
Analyst Count
2
5
Target Price
$10.50
$3.23
AVG Volume (30 Days)
978.5K
2.9M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.25
EPS
N/A
N/A
Revenue
N/A
$31,081,000.00
Revenue This Year
N/A
$56.61
Revenue Next Year
$3.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2481.48
52 Week Low
$5.00
$0.28
52 Week High
$17.58
$1.83

Technical Indicators

Market Signals
Indicator
DNA
LXRX
Relative Strength Index (RSI) 34.04 55.19
Support Level N/A $1.07
Resistance Level $10.05 $1.65
Average True Range (ATR) 0.71 0.09
MACD -0.14 0.02
Stochastic Oscillator 0.81 64.44

Price Performance

Historical Comparison
DNA
LXRX

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: